Oncology

Importantly, when considering the useof small molecule inhibitors, potential drug interactions must be evaluated.

The mitomycin gel is an alkylating drug, inhibiting the transcription of DNA into RNA and stopping protein synthesis and taking away the cancer cell’s ability to multiply.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

In patients with BRCA wild type carcinomas, treatment with veliparib was beneficial even at low homologous recombination deficiency scores compared with carboplatin and paclitaxel.

The addition of pazoparib to gemcitabine enhances anti-tumor activity, particularly for patients with platinum-resistant disease who derived the most benefit from combination therapy, even in the setting of receiving prior bevacizumab.

A new study investigated the molecular impact of the cancer-killing PARP-1 inhibitor (PARPi) binding to PARP-1 and found that the drug can be structurally modified to increase its power to kill tumor cells.

The results of this study resonate other results, suggesting that 3D mammograms are more accurate than 2D mammograms and may help 3D mammography become part of routine breast cancer screening.

The JAVELIN trial is a randomized, open-label, phase 3 trial comparing avelumab in combination with chemotherapy versus chemotherapy alone.

Approximately 1 in 40 postmenopausal women diagnosed with breast cancer before the age of 65 had a mutation linked to cancer in the BRCA1 or BRCA2 gene, according to an analysis of data from the Women’s Health Initiative (WHI).

Researchers presented findings in conjunction with the Society of Gynecologic Oncology 2020 Annual Meeting on Women’s Cancer on the phase 3 VELIA trial studying the safety of veliparib.

Check out these pre- and postimplementation checklists, which also help to justify the investment.

Although testing and vaccination for the human papillomavirus have decreased the number of cervical cancer deaths, the disease remains the fourth most common cancer type in women.

The industry has concentrated its efforts on developing new therapies with few or no competitors.

Demcizumab is a DLL4-targeted lgG2 humanized monoclonal antibody and a potent inhibitor of the Notch pathway.

COA released a statement explaining that it fundamentally opposes home infusion of chemotherapy, cancer immunotherapy, and cancer treatment supportive drugs due to concerns regarding the safety of patients in such an environment.

Medically integrated pharmacies with access to the EMR incorporate this information into the treatment plan.

By mining a vast trove of genetic data, researchers are enhancing physicians’ ability to treat cancer, predict patient outcomes, and determine which treatment will work best for individual patients.

The CLIO trial evaluated olaparib single-agent therapy versus standard-of-care chemotherapy in platinum-sensitive recurrent epithelial ovarian cancer.

The FDA has approved encorafenib in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation after prior therapy.

Consuming a diet high in fiber was linked with a reduced incidence of breast cancer in an evaluation of all relevant studies, according to findings published in CANCER.

Cervical cancer screening rates in Japan were significantly affected in the years following the devastating Great East Japan Earthquake of 2011, suggesting that disasters can affect cervical cancer screening for years.

The objective of the study was to analyze whether USC would be uniquely sensitive to further interference of cell cycle regulation by Wee1 inhibition.

Cases studies focused on medication reconcilliation for patients with breast cancer.

During this period, 1834 participants developed lung cancer, of whom 290 had COPD and 1544 did not, according to the researchers.

Directions in Pharmacy® is a full-day regional conference for community and health-system pharmacists.

Oncology pharmacists can prevent errors that occur when a patient’s medications include prescription drugs, OTC medications, herbals, and dietary supplements.

The objective of the study was to find whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after first-line (1L) platinum-based chemotherapy (CT).

XMT-1536, a first-in-class antibody-drug conjugate NaPi2B was well tolerated with no dose-limiting toxicities in patients with ovarian cancer and non-small cell lung cancer (NSCLC).

However, the magnitude of the progression-free survival (PFS) benefit is greatest when surgery achieved complete surgical debulking, specifically in the upfront setting.

The objective of the study was to analyze whether niraparib improves PFS in patients with newly diagnosed advanced ovarian cancer after response to first-line platinum-based chemotherapy.